Objective To observe the effect of tislelizumab combined with pemetrexed and cisplatin in the treatment of stage Ⅳ non-small cell lung cancer(NSCLC).Methods Seventy patients with stage Ⅳ NSCLC admitted to Bengbu First People's Hospital from July 2021 to July 2024 were selected and randomly divided into the study group and the conventional group by the coin-tossing method,with 35 cases in each group.The conventional group was treated with pemetrexed+cispla-tin,while the study group was treated with tislelizumab on the basis of the conventional group.The treatment courses for both groups were 12 weeks.The short-term therapeutic effects,T cell subsets(CD3+,CD4+,CD8+,CD4+/CD8+),tumor markers(CA125,VEGF,CYFRA21-1,CEA,NSE),quality of life(FACT-L score)before and after treatment,and adverse reac-tions were compared between two groups.Results The objective response rate of the study group was 88.57％,which was higher than 65.71％of the conventional group(x2=5.185,P=0.023).After 12 weeks of treatment,CD3+,CD4+and CD4+/CD8+in both groups were higher than those before treatment,CD8+were lower than those before treatment,and the study group were higher/lower than the conventional group(P＜0.01).The levels of serum CA125,VEGF,CYFRA21-1,CEA and NSE in two groups were lower than those before treatment,and those in the study group were lower than those in the conventional group(P＜0.01).The scores of each dimension of FACT-L in both groups were higher than those before treat-ment,and the scores in the study group were higher than those in the conventional group(P＜0.05 or P＜0.01).There was no statistically significant difference in the total incidence of adverse reactions between the study group and the conventional group(11.43％vs.22.86％,x2=1.609,P=0.205).Conclusion Tislelizumab combined with pemetrexed and cisplatin in the treatment of stage Ⅳ NSCLC can increase the objective response rate,improve T cell subsets and tumor markers,enhance the quality of life of patients,and has a low safety risk.
维普
万方数据